GlassScriptPhysician profile
Stacey Lip
NPI 1962421115
$5,570.45
in general payments reported to CMS, 2019-2025
24 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $1,108 · 2023: $1,373 · 2024: $1,231 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,015.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $1,431.39 | 2021-2025 | Imcivree, Imcivree |
| Abbvie INC. | $884.05 | 2021-2025 | |
| Novo Nordisk INC | $609.23 | 2021-2025 | Wegovy, Sogroya |
| Tolmar Pharmaceuticals, INC. | $437.83 | 2021-2022 | |
| Tolmar, INC. | $372.44 | 2023-2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $337.14 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $277.94 | 2022-2025 | Skytrofa |
| Alexion Pharmaceuticals, INC. | $193.44 | 2021-2023 | Strensiq |
| Merck Sharp & Dohme LLC | $185.09 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Cranial Technologies, INC | $141.71 | 2021-2025 | Doc Band |
| Sobi, INC | $111.36 | 2021-2024 | |
| Kyowa Kirin, INC. | $97.10 | 2023-2025 | Crysvita |
| Phadia US INC. | $72.89 | 2023-2025 | Immunocap |
| Azurity Pharmaceuticals, INC. | $72.05 | 2022-2025 | Triptodur |
| Glaxosmithkline, LLC. | $57.77 | 2024-2025 | Bexsero |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $56.85 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $51.32 | 2022-2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $42.18 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $33.81 | 2022-2023 | |
| Pfizer INC. | $26.55 | 2022-2023 | |
| Dexcom, INC. | $26.16 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $23.09 | 2024 | |
| Eton Pharmaceuticals, INC. | $15.08 | 2023 | Alkindi |
| Abbott Laboratories | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Lip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.